

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

APOTEX INC., APOTEX CORP., ARGENTUM PHARMACEUTICALS
LLC, ACTAVIS ELIZABETH LLC, TEVA PHARMACEUTICALS USA,
INC., SUN PHARMACEUTICAL INDUSTRIES, LTD., SUN
PHARMACEUTICAL INDUSTRIES, INC., AND SUN PHARMA GLOBAL
FZE,
Petitioners,

v.

NOVARTIS A.G.,
Patent Owner.

IPR2017-00854¹
Patent No. 9,187,405

**PETITIONERS' REQUEST FOR ORAL ARGUMENT PURSUANT
TO 37 C.F.R. § 42.70**

¹ Cases IPR2017-01550, IPR2017-01946, and IPR2017-01929 have been joined
with this proceeding.

Case IPR2017-00854
Patent 9,187,405

Pursuant to 37 C.F.R. § 42.70(a), Petitioners request that the Board grant oral argument for IPR2017-00854 on the instituted grounds against the involved claims, the proposed amended claims, any issues raised in Petitioners' Papers or Patent Owner's Papers, and on any pending motions.

Petitioners request one hour per side of oral argument. The Oral Argument is scheduled to be held May 11, 2018 pursuant to the Board's Order of October 6, 2017 (Paper 25).

Respectfully submitted,

Date: April 17, 2018

/ Steven W. Parmelee /
Steven W. Parmelee, Lead Counsel
Reg. No. 31,990

Case IPR2017-00854
Patent 9,187,405

CERTIFICATE OF SERVICE

I certify that the foregoing Petitioners' Request for Oral Argument Pursuant to 37 C.F.R. § 42.70 was served on this 17th day of April, 2018, on the Patent Owner at the electronic service addresses of the Patent Owner as follows:

Jane M. Love, Ph.D.
Robert W. Trenchard
GIBSON, DUNN & CRUTCHER LLP
200 Park Avenue, 47th Floor
New York, NY 10166
Email: jlove@gibsondunn.com
Email: rtrenchard@gibsondunn.com

Respectfully submitted,

Date: April 17, 2018

/ Steven W. Parmelee /
Steven W. Parmelee, Lead Counsel
Reg. No. 31,990